Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Trial Profile

A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs NCI-4650 (Primary)
  • Indications Cancer; Gastrointestinal cancer; Genitourinary disorders; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2018 Planned initiation date changed from to (estimated date for recruitment of the first subject) changed from 16 may 2018 to 23 may 2018.
    • 11 May 2018 Planned initiation date changed from 3 May 2018 to 16 May 2018.
    • 27 Apr 2018 Planned initiation date changed from to (estimated date for recruitment of the first subject) changed from 1 May 2018 to 3 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top